A prospective cohort study has demonstrated that the most used β-ARs antagonist, propranolol, an approved drug with a non-oncology primary purpose, protected patients with thick cutaneous melanoma from melanoma recurrence [75]. This evidence concerns the gene CTBP1 and melanoma.